The reported frequency of PTEN deletion in prostate cancer varies widely, most likely as a result of differences in tissue preparation, stage of disease, and the methodology used to detect molecular aberrations (Yoshimoto et al, 2006a). The gene discussed is PTEN; the disease is prostate cancer.